Cel­gene ex­ec jumps to head blue­bird bio ops in Eu­rope, where its $1.8M gene ther­a­py Zyn­te­glo is now avail­able

Days af­ter shak­ing hands with Ger­man reg­u­la­tors over the launch and cov­er­age of its be­ta-tha­lassemia gene ther­a­py, blue­bird bio has wooed a Cel­gene ex­ec to lead its Eu­ro­pean op­er­a­tions.

Nico­la Hef­fron, a bio­phar­ma vet with stints across Eli Lil­ly, GSK and Shire, jumps from a brief tenure over­see­ing mar­ket­ing for Cel­gene’s myeloid port­fo­lio in Sum­mit, NJ. She will now be based in Zug, Switzer­land.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.